Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

ANACOR (ANAC) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of Anacor Pharmaceuticals, Inc.; Are Shareholders Getting a Fair Price?

PR Newswire May 16, 2016

Pfizer to Acquire Anacor

Business Wire May 16, 2016

Pfizer Presents Results from Two Phase 3 TRUMENBA® (Meningococcal Group B Vaccine) Studies at the European Society for Paediatric Infectious Diseases Meeting

Business Wire May 13, 2016

Pfizer Awards More Than $1 Million in Metastatic Breast Cancer Research Funding Through Breast Cancer: A Story Half Told Initiative

Business Wire May 11, 2016

PFIZER REPORTS FIRST-QUARTER 2016 RESULTS

Business Wire May 3, 2016

Pfizer Hosts Annual Meeting of Shareholders

Business Wire April 28, 2016

Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled

Business Wire April 26, 2016

CHANTIX®/CHAMPIX® (varenicline) Results from the Largest Global Clinical Trial of Smoking Cessation Medicines Published in The Lancet

Business Wire April 22, 2016

Pfizer Invites Public to Listen to Webcast of April 28 Annual Meeting of Shareholders

Business Wire April 21, 2016

Pfizer Announces Positive Top-Line Results for Phase 3 PALOMA-2 Clinical Trial of IBRANCE® (palbociclib)

Business Wire April 19, 2016

On the Latest BizWireTV Cars Get Night Vision and Healthy Eating Made More Accessible

Business Wire April 15, 2016

A.M. Best Affirms Ratings of Blue Whale Re Ltd.

Business Wire April 7, 2016

Pfizer Taps IBM for Research Collaboration to Transform Parkinson's Disease Care

Business Wire April 7, 2016

New Tax Inversions Rules: Threats To Healthcare ETFs?

Benzinga.com  April 6, 2016

PPH May Be Home To Hedge Fund Hotels, But This ETF Can Endure

Benzinga.com  April 6, 2016

Pfizer Receives European Approval for New Multi-Dose Vial Presentation of Prevenar 13®

Business Wire April 6, 2016

Pfizer Announces Termination of Proposed Combination with Allergan

Business Wire April 6, 2016

Allergan Reiterates Strong Standalone Growth Profile and Strategy Following Termination of Pfizer Transaction

PR Newswire April 6, 2016

FDA Approves INFLECTRA(TM) (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications

Business Wire April 5, 2016

Merck KGaA, Darmstadt, Germany, and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma

Business Wire April 5, 2016